Atlas Trials

Osimertinib Treatment on EGFR T790M Plasma Positive NSCLC Patients (APPLE)

Clinical trial NCT02856893 · COMPLETED

Trial details

NCT number
NCT02856893
Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
NSCLC
Start date
2017-10-10
Primary completion
2022-09-20
Enrollment
156

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.